<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02312375</url>
  </required_header>
  <id_info>
    <org_study_id>Fimasartan study</org_study_id>
    <nct_id>NCT02312375</nct_id>
  </id_info>
  <brief_title>Effects of Fimasartan on Insulin Secretion in Type 2 Diabetic Patients</brief_title>
  <official_title>Effects of Fimasartan on Insulin Secretion, and Interaction With DPP4 Inhibitors in Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to evaluate the effect of ARB in improving insulin secretion in
      patients with type 2 diabetes. The investigators also aimed to evaluate if there are
      potential synergisms between ARB and DPP4 inhibitors in improving insulin secretion and
      urinary albumin secretion in diabetic patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Angiotensin II has been reported to insulin secretion in beta cells. Angiotensin II
      indirectly improves insulin secretion in beta cells via vasoconstriction and reduced islet
      blood flow. Chronic exposure to high glucose or high fat increases expression of AT1R
      (angiotensin type 1 receptor), leading to reactive oxidative stresses, inflammation, and
      apoptosis in beta cells, finally decreased insulin formation and secretion. Some studies
      showed the beneficial effect of blocking AT1R on insulin secretion and beta cell
      proliferation in animal models using angiotensin receptor blocker (ARB). Furthermore, 26
      weeks of valsartan treatment improved insulin secretion in humans with impaired glucose
      regulation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulinogenic index</measure>
    <time_frame>16 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>HOMA β-cell function</measure>
    <time_frame>16 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin resistance</measure>
    <time_frame>16 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary albumin creatinine ratio, urinary protein creatinine ratio</measure>
    <time_frame>16 week</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Fimasartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Expreimental drug is fimasartan.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amlodipine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active comparator is amlodipine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fimasartan</intervention_name>
    <description>16 weeks of fimasartan vs. amlodipine followed by 2 weeks of wash-out period, then crossover</description>
    <arm_group_label>Fimasartan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine</intervention_name>
    <description>16 weeks of fimasartan vs. amlodipine followed by 2 weeks of wash-out period, then crossover</description>
    <arm_group_label>Amlodipine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 20~80 years

          -  Type 2 diabetic patients diagnosed more than 6 months ago

          -  HbA1c ≤8.5% at screening

          -  No change of OAD within the 3 months before screening

          -  SBP &lt;140 mmHg and DBP &lt;90 mmHg with anti-hypertensive drug at screening

          -  SBP ≥140 mmHg or DBP ≥80 mmHg without anti-hypertensive drug at screening

        Exclusion Criteria:

          -  Type 1 diabetic patients or active insulin treatment at screening

          -  Treatment with ARB or ACEi within 1 month prior to screening

          -  Uncontrolled hypertension with SBP &gt;170 mmHg or DBP &gt;100 mmHg

          -  Pregnancy or lactation

          -  Elevated liver enzyme (AST or ALT &gt; 3 times the UNL) or elevated serum Cr (≥1.5 mg/dL
             in men and 1.4 mg/dL in women)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-144</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2014</study_first_submitted>
  <study_first_submitted_qc>December 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2014</study_first_posted>
  <last_update_submitted>April 27, 2017</last_update_submitted>
  <last_update_submitted_qc>April 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Hye Seung Jung</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

